Bristol Myers Squibb’s Reblozyl® (luspatercept) Receives Positive CHMP Opinion for Anemia Treatment in Low- to Intermediate-Risk MDS Adults
Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Reblozyl® (luspatercept) for…
Celltrion Reveals New Two-Year Results of Subcutaneous Infliximab (CT-P13 SC) for Treating Inflammatory Bowel Disease (IBD) at 19th ECCO Congress
Celltrion presented encouraging findings from the extensive LIBERTY studies, including LIBERTY-CD 1 and LIBERTY-UC 2, focusing on patients with Alzheimer’s disease, Crohn’s disease (CD), or moderately to severely active ulcerative…
Ironwood Pharmaceuticals to Showcase Four Abstracts at ASPEN’s 2024 Nutrition Science & Practice Conference
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company specializing in gastrointestinal healthcare, has revealed plans to present findings from four studies examining apraglutide in adults diagnosed with short bowel syndrome with…
Bristol Myers Squibb Reports Conclusion of RayzeBio Tender Offer Period
Bristol Myers Squibb (NYSE: BMY) has confirmed the conclusion of its tender offer, initially announced, to acquire all outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock at a price…
FDA Prioritizes Review of Dupixent® sable for COPD Treatment Targeting Type 2 Inflammation
The U.S. Food and Drug Administration (FDA) has given priority review status to the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab), marking its sixth potential indication. This review targets…
Sanofi’s Board of Directors Recommends Clotilde Delbos, Anne-Françoise Nesmes, and John Sundy as Independent Directors
Sanofi’s Board of Directors has announced its intentions for the upcoming General Shareholder Meeting on April 30, 2024. The board proposes the renewal of Rachel Duan and Lise Kingo’s terms,…
Acquisition of Gracell completed
AstraZeneca Completes Acquisition of Gracell Biotechnologies Inc., Expanding Cell Therapy Portfolio AstraZeneca has successfully finalized the acquisition of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a prominent global biopharmaceutical company specializing…
KEYTRUDA® Granted Favorable EU CHMP Opinion for NSCLC Treatment
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
AbbVie and Tentarix Partner to Innovate Conditional Multi-Specific Biologics for Oncology and Immunology
AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics have unveiled a significant collaboration aimed at pioneering the development of conditionally-active, multi-specific biologics targeting oncology and immunology. This strategic alliance will harness…
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils 2024 Grant Initiative to Empower Female Entrepreneurs
Today, Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has officially launched the application process for its 2024 BOTOX® Cosmetic grant program, aimed at supporting women entrepreneurs. Following a successful…
Understanding Heart Failure: It’s Likely Not What You Imagine
Carlos Mercado experienced a sudden onset of symptoms reminiscent of a heart attack while settling down for an evening of television in 2022. The racing heart, chest pain, and cold…
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of oral, small molecule protease inhibitors, has announced today that the UK Medicines and…